Vasculitis

Immunology·MeSH: Vasculitis

Prevalence

5.0 / 100K

12 drugs in development·10 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
bdb-001	Eiger BioPharmaceuticals, Inc. (EIGR)

Phase 2(5)

Drug	Company
FT819	FATE THERAPEUTICS INC (FATE)
rapcabtagene autoleucel	Novartis AG (NVS)
sparsentan	Travere Therapeutics, Inc. (TVTX)
tarperprumig	ALEXION PHARMACEUTICALS, INC. (ALXN)
Tarperprumig	ARS Pharmaceuticals, Inc. (SPRY)

Phase 1(3)

Drug	Company
CC-97540	Merus N.V. (MRUS)
FT819	Filana Therapeutics Inc. (FLNA)
prula-cel	Adicet Bio, Inc. (ACET)

Phase 4(3)

Drug	Company
Avacopan	AMGEN INC (AMGN)
No sparsentan	Travere Therapeutics, Inc. (TVTX)
rapcabtagene autoleucel single agent	Novartis AG (NVS)

BioSniper tracks 12 drugs in development for Vasculitis across 10 companies.

There are 1 clinical trial targeting Vasculitis tracked by BioSniper.

The estimated prevalence of Vasculitis is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.